Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
NCT ID: NCT03299244
Last Updated: 2021-04-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
637 participants
INTERVENTIONAL
2018-05-15
2020-04-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
NCT01896232
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
NCT01932970
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
NCT01788046
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
NCT01785849
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
NCT03283098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cinacalcet
Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
Cinacalcet
Cinacalcet administered orally once a day.
Etelcalcetide
Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
Etelcalcetide
Administered intravenously three times per week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etelcalcetide
Administered intravenously three times per week.
Cinacalcet
Cinacalcet administered orally once a day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female subjects ≥ 18 years of age or older at the time of signing informed consent.
* Subject must be receiving maintenance hemodialysis 3 times weekly for at least 3 months, with adequate hemodialysis based on a delivered measure of dialysis adequacy (Kt/V) ≥ 1.2 or urea reduction ratio ≥ 65% within 4 weeks prior to screening laboratory assessments. The Kt/V formula used for a subject must be the formula used during routine care prior to screening.
* Dialysate calcium concentration must be ≥ 2.5 mEq/L (1.25 mmol/L) and stable for at least 4 weeks prior to screening laboratory assessments, and must remain ≥ 2.5 mEq/L (1.25 mmol/L) for the duration of the study.
* Subject must have SHPT as defined by one central laboratory screening predialysis serum PTH value \> 500 pg/mL, within 2 weeks prior to randomization.
* Subject currently receiving vitamin D sterols must have had no more than a maximum dose change of 50% within the 4 weeks prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable doses for the duration of the study, except for adjustments allowed per protocol or for safety reasons.
* Subject must have 1 screening predialysis serum cCa laboratory value ≥ 8.3 mg/dL measured within 2 weeks prior to randomization.
* A subject receiving calcium supplements must have had no more than a maximum dose change of 50% within 2 weeks prior to screening laboratory assessments and remain stable through randomization.
* A subject receiving phosphate binders must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable dose for the duration of the study, except for adjustments allowed per protocol or for safety reasons.
Exclusion Criteria
* Subject has received etelcalcetide in a prior clinical trial of etelcalcetide.
* Subject has received cinacalcet during the 3 months prior to the first screening laboratory assessments.
* Subject has known sensitivity to any of the products or components of either cinacalcet or etelcalcetide to be administered during dosing.
* Subject has previously been randomized in this study.
* Anticipated or scheduled parathyroidectomy during the study period.
* Subject has received a parathyroidectomy within 6 months prior to dosing.
* Anticipated or scheduled kidney transplant during the study period.
* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
* Malignancy within the last 5 years of screening (except non-melanoma skin cancers or cervical carcinoma in situ).
* Grapefruit juice is prohibited.
* Subject is pregnant or nursing, or planning to become pregnant or nurse during treatment or within 3 months after the last dose of etelcalcetide or 30 days after the last dose of cinacalcet
* Female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during treatment with investigational product (IP) through 3 months after the last dose of IP.
* Subject has a history of symptomatic ventricular dysrhythmias or Torsades de Pointes.
* Subject has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening.
* Subject has clinically significant abnormalities on prestudy clinical examination or abnormalities on the most recent central laboratory tests during the screening period prior to randomization according to the Investigator including but not limited to the following:
* serum albumin \< 3.0 g/dL
* serum magnesium \< 1.5 mg/dL
* serum transaminase (alanine transaminase \[ALT\] or serum glutamic pyruvic transaminase \[SGPT\], aspartate aminotransferase \[AST\] or serum glutamic oxaloacetic transaminase \[SGOT\]) \> 3 times the upper limit of normal (ULN) at screening.
* Subject likely not available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and Investigator's knowledge.
* History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Beijing, Beijing Municipality, China
Research Site
Lanzhou, Gansu, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
Research Site
Zhanjiang, Guangdong, China
Research Site
Nanning, Guangxi, China
Research Site
Nanning, Guangxi, China
Research Site
Zhengzhou, Henan, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Wuhan, Hubei, China
Research Site
Wuhan, Hubei, China
Research Site
Changsha, Hunan, China
Research Site
Changsha, Hunan, China
Research Site
Changzhou, Jiangsu, China
Research Site
Nanjing, Jiangsu, China
Research Site
Nanjing, Jiangsu, China
Research Site
Wuxi, Jiangsu, China
Research Site
Changchun, Jilin, China
Research Site
Changchun, Jilin, China
Research Site
Dalian, Liaoning, China
Research Site
Dalian, Liaoning, China
Research Site
Dalian, Liaoning, China
Research Site
Shenyang, Liaoning, China
Research Site
Shenyang, Liaoning, China
Research Site
Xi'an, Shaanxi, China
Research Site
Qingdao, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Taiyuan, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Ürümqi, Xinjiang, China
Research Site
Hangzhou, Zhejiang, China
Research Site
Hangzhou, Zhejiang, China
Research Site
Hong Kong, , Hong Kong
Research Site
Kowloon, , Hong Kong
Research Site
New Territories, , Hong Kong
Research Site
Ahmedabad, Gujarat, India
Research Site
Nadiād, Gujarat, India
Research Site
Belagavi, Karnataka, India
Research Site
Mysuru, Karnataka, India
Research Site
Kozhikode, Kerala, India
Research Site
Kozhikode, Kerala, India
Research Site
New Delhi, National Capital Territory of Delhi, India
Research Site
New Delhi, National Capital Territory of Delhi, India
Research Site
New Delhi, National Capital Territory of Delhi, India
Research Site
New Delhi, National Capital Territory of Delhi, India
Research Site
Chandigarh, Punjab, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Lucknow, Uttar Pradesh, India
Research Site
Dehradun, Uttarakhand, India
Research Site
Wardha, , India
Research Site
Ipoh, Perak, Malaysia
Research Site
George Town, Pulau Pinang, Malaysia
Research Site
Kuching, Sarawak, Malaysia
Research Site
Batu Caves, Selangor (incl. Putrajaya), Malaysia
Research Site
Busan, , South Korea
Research Site
Busan, , South Korea
Research Site
Daegu, , South Korea
Research Site
Gumi-si, Gyeongsangbuk-do, , South Korea
Research Site
Guri-si, Gyeonggi-do, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Changhua, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Keelung, , Taiwan
Research Site
New Taipei City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20150238
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.